Tepotinib domestic launch time

Tepotinib is a targeted therapy drug mainly used to treat metastatic non-small cell lung cancer (NSCLC) carrying exon 14 skipping mutations of the mesenchymal epidermal transforming factor receptor (MET). The drug was developed by the German pharmaceutical company Merck (Merck KGaA) and will be officially launched in China in 2021.

The launch of tepotinib is one of the results of the reform of China’s drug review and approval system. In recent years, China's National Medical Products Administration (NMPA) has accelerated the review and approval of new drugs in order to introduce internationally advanced treatments into the country more quickly. Tepotinib was approved by NMPA in 2021, marking an important step in the field of cancer treatment in China.

The clinical trial data of tepotinib is an important basis for its approval. The VISION study is a pivotal, multicenter, single-arm, open-label clinical trial evaluating the efficacy and safety of tepotinib in patients with METexon14 skipping mutations in advanced NSCLC patients. The study results show that tepotinib has a significant objective response rate (ORR) and durable therapeutic effect in such patients. Based on these data, tepotinib has also gained wide recognition in the European and American markets and has been rapidly promoted and applied globally.

The launch of Tepotinib in China provides a new treatment option for NSCLC patients carrying MET mutations. Compared with traditional chemotherapy and other treatments, Tepotinib has higher targeting and can more effectively inhibit the growth and spread of tumor cells while reducing damage to normal cells. This is of great significance for improving patients' quality of life and prolonging survival.

Although the introduction of tepotinib into the Chinese market is an important milestone, attention still needs to be paid to its safety and efficacy in long-term use. Adverse drug reactions, such as edema, nausea, diarrhea, fatigue, and abnormal liver function, require continuous monitoring and management in clinical practice. Meanwhile, further studies are underway to explore the potential use of tepotinib in other types of cancer.